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Background: Fine needle aspiration (FNA) of thyroid nodules is a cornerstone of surgical decision making in
thyroid cancer. The most widely utilized system for reporting thyroid FNA results is the Bethesda System, which
includes predicted malignancy rates for each FNA category. To date there have been few studies to determine
whether these predictions are widely applicable.
Methods: All thyroid FNA results at the Queen Elizabeth II Health Science Centre from 2006–2010 were included in
this study. The results were tabulated by FNA category and the health records were reviewed to determine
whether the patient went on to have surgery and the result of surgical histopathology. Rates of malignancy were
calculated and compared to published values.
Results: A total of 1491 thyroid FNAs were included in the study, representing 1117 individual patients with
available health records. The majority of these FNAs were Benign, but the proportion of Unsatisfactory FNAs was
higher than predicted while Malignant and Suspicious for Malignancy were lower than predicted. Surgery was
performed on 388 patients and 110 were positive for malignancy (28%). The malignancy rate for each FNA
category was higher than predicted based on literature values.
Conclusions: The proportions of FNA diagnoses and the rates of malignancy for each FNA category at our
institution were not consistent with predicted values. It is important for clinicians to base their surgical
recommendations on institution specific malignancy rates, not solely on literature values.
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Thyroid cancer has the most rapidly increasing inci-
dence of all major cancers in Canada [1]. Part of this
increased incidence is attributable to earlier detection of
thyroid nodules with improved diagnostic imaging tech-
niques. The majority of thyroid nodules are benign but
all warrant investigation to rule out malignancy. Assess-
ment of thyroid nodules is a common reason for referral
to an otolaryngologist. Early detection and treatment of
malignant nodules is associated with excellent outcomes
[1]. Currently, treatment decisions for thyroid nodules
rely heavily on the results of fine needle aspiration
(FNA) of the thyroid.
Fine needle aspiration is an important diagnostic tool
in the evaluation of thyroid nodules. This cytological test* Correspondence: drbwilliams@gmail.com
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reproduction in any medium, provided the oris widely available and easy to perform in an outpatient
setting. The result of an FNA is a cornerstone in deter-
mining whether to perform surgery and which type of
surgery to offer (i.e., hemithyroidectomy or total thyroid-
ectomy). A key factor in the application of FNA results
is consistency among reports. As interpretation of
thyroid FNAs evolved, a number of systems were developed
to categorize the results. The most recent and most widely
used approach is the Bethesda System. With the release of
the Bethesda guidelines, there now exists a standard
schema for the classification of thyroid cytologic specimens
[2]. This has been a great advance in the treatment of
thyroid cancer.
The Bethesda System defines 6 categories: non-diagnostic,
benign, atypia of undetermined significance (AUS), sus-
picious for a follicular neoplasm (SFN), suspicious for malig-
nancy (SFM), and malignant. The Bethesda system is not
just a classification system but also goes into great detaill Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The distribution of thyroid FNAs by diagnostic
category, with percentage in parentheses







FNA – fine needle aspiration, SFN – Suspicious for Neoplasm, SFM – Suspicious
for Malignancy.
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each FNA. The system also details the risk of malignancy
for each category, based on large patient series, as well as
the suggested management for each FNA result. Though
this system has been widely adopted, there has been little
research to audit whether the actual risks of malignancy
are consistent with those reported. There have been no
Canadian studies to determine whether the published risks
of malignancy are applicable in Canada. Despite this,
patients are often counseled and operative recommenda-
tions made based on Bethesda data.
Given the pivotal role played by FNA in the work-up
of a thyroid nodule, it is important to ensure that this
tool is providing reliable data. There have been a small
number of American studies that compared the results
of the preoperative thyroid FNA to the final histology
after surgical excision of the gland [3-5]. This provides
an estimate of the accuracy of the FNA. These studies
have largely supported the clinical utility of FNAs but broad
application of their results is difficult given differences
among centers and systemic differences between Canada
and the United States.
We undertook an audit of our thyroid FNA results to
determine whether our results were consistent with the
Bethesda System and with literature values from large
series in the literature. Our goals were to provide quality
assurance by describing the various proportions of diagnoses
made and to improve our surgical decision-making by
having an accurate picture of malignancy risks at our institu-
tion. The setting is a tertiary care center in Canada that is
representative of other such centers in Canada.
Methods
Institutional research ethics board approval was obtained.
All patients who received FNA of the thyroids between
2006 and 2010 were included in our database. Investiga-
tion of thyroid nodules at our institution follows esta-
blished guidelines from the American Thyroid Association
[6]. The results of their FNA, whether or not they went on
to have surgery, and the results on surgical pathology were
collected. The cytopathological system used at our institu-
tion was slightly different from Bethesda in that is used 5
diagnostic categories, grouping AUS and SFN together
into Abnormal. We were able to extrapolate the SFN
results based on pathologist comments to arrive at six
categories that corresponded to the six in the Bethesda
System and in other published studies. Only comments
that included the phrases “Diagnosis favors neoplasm” or
“Suspicious for neoplasm” were categorized as SFN.
Initially 346 FNAs were categorized as Abnormal. Sixty-
five were subsequently extrapolated to SFN (Table 1).
A number of the surgical specimens contained papil-
lary thyroid microcarcinoma (i.e., a focus less than 1 cm
in greatest diameter). These were categorized as benignif there was no macroscopic cancer present because the
sub-centimeter foci would not be targeted by FNA. In
analyzing the malignancy rates, if an individual patient
received multiple FNAs, the most worrisome FNA result
was used when comparing to surgical pathology.
Our two major outcomes were 1) what proportion of
all thyroid FNAs does each category represent and 2) for
patients who go on to surgery, the rate of malignancy
within each FNA category.
Our results were tabulated in Microsoft Excel and per-
centages calculated. The results were compared to the
Bethesda System and to other large studies. The Bethesda
System gives ranges for risk of malignancy. We used the
midpoint of the range for our graphic comparisons.
Results
Between April 2006 and December 2010, there were
1491 thyroid FNAs interpreted at our centre. The distri-
bution of FNA results by category is reported in Table 1.
There were 1167 individual patients represented in the
above values, as some had repeat FNAs. Of these
patients, 1117 had health records of their surgery available,
915 female and 202 male. Of these patients, 388 (38.5%)
went on to have thyroid surgery: 246 hemithyroidec-
tomies, 127 total thyroidectomies, 13 completion thyroid-
ectomies, and 2 open biopsies. Of those patients who
received surgery 110 had malignancy, for an overall malig-
nancy rate of 28.0%. The specific diagnoses were as
follows: 87.3% papillary thyroid cancer, 4.6% follicular
thyroid cancer, 2.7% medullary thyroid cancer, 2.7% renal
cell carcinoma metastases, 1.8% lymphoma, and 0.9%
poorly differentiated thyroid cancer. The correlation of
FNA category to surgical pathology for these patients is
reported in Table 2.
Discussion
This study presents a thorough audit of thyroid FNA
and associated malignancy rates at a Canadian tertiary
care canter. Our findings suggest that the distribution of
FNA diagnoses is not consistent with large American
patient series and the malignancy rates are not
Table 2 Correlation of FNA category to surgical
pathology and overall malignancy rate for each category
FNA
category
Surgical pathology (%) Malignancy
rate (%)PTC FTC MTC Other
Unsatisfactory 14.5 0.0 0.0 3.6 18.2
Benign 14.9 0.0 0.0 1.1 16.0
Abnormal 22.2 1.2 0.6 0.6 24.7
SFN 23.9 6.5 0.0 2.2 32.6
SFM 76.5 0.0 11.8 5.9 94.1
Malignant 100.0 0.0 0.0 0.0 100.0
Values are expressed as percentages of all FNAs in each category. FNA – fine
needle aspiration, SFN – Suspicious for Neoplasm, SFM – Suspicious
for Malignancy.
Table 4 Comparison of malignancy rates by FNA category
among this study, the Bethesda System, and published

















Unsatisfactory 18.2 1-4 10.9 8.9 14
Benign 16.0 0-3 7.3 6.5 3
Abnormal 24.7 5-15 13.5 17 6
SFN 32.6 15-30 32.2 25.4 22
SFM 94.1 60-75 64.7 70 56
Malignant 100.0 97-99 98.6 98.1 100
Overall 28.4 – 45.3 31.3 29.0
FNA – fine needle aspiration, SFN – Suspicious for Neoplasm, SFM – Suspicious
for Malignancy.
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when making treatment recommendations and counsel-
ing patients, surgeons should use data from their own
institution in addition to published values.
A 2007 study from Yang et al. correlated FNA results
with surgical histology in series of 4703 patients from
two institutions [3]. In this series, 1072 patients went on
to have surgery and the results from those patients were
used to estimate malignancy rates. Overall, they found
that thyroid FNA using the Bethesda System to be
accurate and clinically useful in surgical decision-
making. Subsequently, Jo and colleagues published their
findings from a series of 3080 thyroid FNAs [4]. In this
study, 892 cases had post-operative histology available
for comparison. Their results were very similar to those
of Yang and colleagues. More recent research compared
FNA results to histology in a community practice [5].
The results of 1382 thyroid FNAs were summarized
along with the malignancy rates by FNA category for
221 patients who went on to have surgery. The overall
results of this study differed slightly from the larger
studies, possibly due to different practices and resources
available at a community centre. The results of the three
papers outlined above are summarized in Tables 3 and 4.Table 3 Comparison of FNA diagnoses between this study
and the published values in other studies, expressed as a















Unsatisfactory 28.9 10.4 18.6 20.1
Benign 45.7 64.6 59.0 39.0
Abnormal 18.8 3.2 3.4 27.2
SFN 4.4 11.6 9.7 8.4
SFM 1.3 2.6 2.3 2.6
Malignant 0.9 7.6 7.0 2.7
FNA – fine needle aspiration, SFN – Suspicious for Neoplasm, SFM – Suspicious
for Malignancy.A comparison of the distribution of FNA diagnoses in
this study and the above studies is summarized in
Table 3. Though the results are inconsistent among the
published values, this study shows a proportion of non-
diagnostic FNAs that is higher than all the other studies,
and rates of SFM and malignant that are lower than all
the other studies. The high number of non-diagnostic
FNAs may reflect shortcoming in the specimen preser-
vation and preparation and warrants further study
within the institution. Many large centers in the United
States have dedicated cytopathologists for immediate
on-site evaluation of specimen adequacy and resampling
if necessary. The difference could also be explained by
sampling error. Recent studies have shown improved
yield and decreased rate of non-diagnostic FNAs with
routine use of ultrasound guidance of FNAs, compared to
palpation guidance [7,8]. Ultrasound guided FNA of the
thyroid may also be a more cost-effective approach [9].
The low proportion of SFM and malignant is more
concerning. Though it may be due to a difference in the
populations served by the current institution, it may also











Unsatisfactory Benign Abnormal SFN SFM Malignant
Current Study
Bethesda System
Figure 1 Comparison of malignancy rates (in percentages)
between the current study. Bethesda System values are given as
the midpoint from the reported range. FNA – fine needle aspiration,
SFN – Suspicious for Neoplasm, SFM – Suspicious for Malignancy.
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thyroidectomies that should be total thyroidectomies.
This concern is supported by the comparison of malig-
nancy rates among published studies in Table 4. There is
a higher malignancy rate in this study for each of the
FNA categories when compared to both the Bethesda
System and to other published studies. The SFM malig-
nancy rate (94%) is almost as high as malignant (100%),
potentially leading to hemi-thyroidectomies that should
be total, according to the treatment guidelines from the
Bethesda System.
The only follicular thyroid carcinomas encountered in
this study were all classified as abnormal or SFN
(Table 2). This is consistent with classic teaching that
follicular neoplasms fall into an abnormal or atypical
group since cytology cannot detect capsular or vascular
invasion, differentiating adenoma from carcinoma. The
majority of malignancies in the abnormal and SFN
groups, however, were papillary thyroid carcinoma.
Typically, PTC should be categorized as SFM or Malig-
nant. These cases were reviewed specifically and all
cases of PTC categorized as abnormal or SFN were
follicular variant of PTC, a subtype that has long posed
diagnostic challenges for cytopathologists.
Another interesting finding in the abnormal and the
extrapolated SFN categories was the much higher malig-
nancy rate in the SFN group: 25% versus 33%. The num-
ber of FTC lesions was also much higher in the SFN
group: 1.2% versus 6.5% of cases. This indicates that at
our centre an additional category would be useful in risk
stratifying patients with indeterminate FNA results.
The malignancy rates are considerably higher in the
present series for Benign and Non-diagnostic FNAs,
compared to Bethesda (Figure 1). Though an interesting
result, a major factor in this difference is attributable to
selection bias. In the Bethesda System, they report the
malignancy risk for all comers. For our study the malig-
nancy rates were determined from those patients who
underwent surgery. The majority of patients with Benign
and Non-diagnostic FNAs did not receive surgery; only
those with worrisome features clinically or on ultrasound.
Though this study provides much useful information,
there are a number of inherent limitations. The system
to categorize thyroid FNA results at our institution
is not the same as the Bethesda System. Though we
extrapolated analogous categories, it is not a perfect
match. Furthermore, our extrapolated category likely
under-represents the number of FNAs that would be
categorized as SFN due to the high degree of variability
in the detail in the pathologist comment section. As this
is a retrospective study, multiple pathologists of various
levels of experience reviewed the FNAs. Categorizing
papillary thyroid microcarcinoma was also a dilemma in
this study. Though it has clinical significance we electedto categorize an isolated focus as benign. The aim of this
study was to evaluate the quality FNA as a diagnostic
tool. A nodule less than 1 cm in diameter would not
have been targeted by FNA during the data collection
period of this study. Current American Thyroid Asso-
ciation guidelines recommend FNA of lesions 0.5 cm or
larger if the patient is high risk. We did not have a full
data set of risk factors for the patients in this study and
so could not retrospectively assign risk categories [6].
Conclusion
The rates of malignancy were considerably higher in this
series than would be predicted by the Bethesda system
and literature values. Extrapolation of other categorization
systems into the Bethesda system will not necessarily
provide rates of malignancy as predicted by Bethesda.
Pathology departments need to make sure that when the
Bethesda system is adopted, the specific criteria for each
category are followed carefully. The difference in malig-
nancy rates could have important implications in patient
care and surgical decision-making. Though it may be
tempting to use values from the ‘best fit’ literature
schemes, this study underscores the importance of using
malignancy rates specific to the institutional classification
system and the population served.
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